<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368468</url>
  </required_header>
  <id_info>
    <org_study_id>19HLSEIN02</org_study_id>
    <nct_id>NCT04368468</nct_id>
  </id_info>
  <brief_title>Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC</brief_title>
  <acronym>MIMOSA</acronym>
  <official_title>Study of the Modifications of the Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative Breast Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prescription of neoadjuvant chemotherapy becomes a standard in women with HER2-positive
      or triple-negative breast cancer and allows a complete histological response (pCR) which
      represents a prognostic factor for survival. . The problem for patients who are not pCR is
      that they are currently receiving non-personalized adjuvant systemic treatment.

      The identification of biomarkers present in the residual disease would be a criterion to
      guide the choice of post-neoadjuvant adjuvant systemic treatment, in order to personalize it.

      At the present time, there is no published study describing extensively the immune
      micro-environment (ME) in breast cancer, whether before or after chemotherapy, nor its
      modification induced by chemotherapy.

      The team therefore propose to study in a retrospective and monocentric series, the
      modifications of the immune ME induced by a &quot;standard&quot; neo-adjuvant chemotherapy in patients
      with triple-negative CS, whether they are in complete histological response or not (n = twice
      50).

      The main objective of this project is to describe the changes in the immune ME of
      triple-negative breast cancers induced by neoadjuvant chemotherapy for all patients (in pCR
      or not):

        -  Quantification of TILs and subtypes of TILs (CD4 and CD8)

        -  Expression of the three immune checkpoints that are PDL1, TIM3 and LAG3

        -  Describe the organization of the immune system (immunostaining on the same slide of the
           PDL1, TIM3 and LAG3 immune checkpoints)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective and monocentric translational study carried out on patients treated at the
      IUCT-Oncopole by neoadjuvant chemotherapy (sequential treatment FEC100 or EC100 then taxane,
      paclitaxel weekly for the most part) for a triple-negative CS between 2012 and 2018.

      We have the microbiopsy of the primary tumor preserved in FFPE and the operating room
      preserved in FFPE.

      We have all the clinical data for the diagnosis and monitoring of these patients, already
      entered into a database.

      The search for a BRCA germline mutation is available in most patients if indicated for an
      oncogenetic consultation.

      biomarkers analysis :

        -  TILS account according to Salgado et al. before and after neoadjuvant chemotherapy

        -  IHC CK5-6 and EGFR then RA if the first two are negative to characterize triple negative
           tumors in &quot;basal-like&quot; and &quot;non-basal-like&quot;

        -  IHC CD3 (labeling of T lymphocytes)

        -  IHC CD4, CD8 and FOXP3 before and after neoadjuvant chemotherapy

        -  PDL1, TIM3 and LAG3 multiplex IHC before and after neoadjuvant chemotherapy

        -  Labeling of tumor cells: AE1 / AE3

        -  Use of markings for exploratory analyzes: CD68 (macrophages), CD39 (marker of lymphocyte
           exhaust
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify Change of immune ME by TILS quantification of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients</measure>
    <time_frame>12 months</time_frame>
    <description>TILS ans substype quantification</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify Change of immune ME by PDL1 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients</measure>
    <time_frame>12 months</time_frame>
    <description>expression of PDL1,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify Change of immune ME by TIM3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients</measure>
    <time_frame>12 months</time_frame>
    <description>expression of TIM3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify Change of immune ME by LAG3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients</measure>
    <time_frame>12 months</time_frame>
    <description>LAG3 expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare change ofTILs quantification of triple-negative breast cancer induced by neoadjuvant chemotherapy for pCR patients and those not pCR and for subtype basal-like or not basal-like</measure>
    <time_frame>12 months</time_frame>
    <description>Quantification of TILs and subtypes TILs;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare change of PDL1 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for pCR patients and those not pCR and for subtype basal-like or not basal-like</measure>
    <time_frame>12 months</time_frame>
    <description>expression of PDL1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare change of TIM3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for pCR patients and those not pCR and for subtype basal-like or not basal-like</measure>
    <time_frame>12 months</time_frame>
    <description>expression of TIM3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare change of LAG3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for pCR patients and those not pCR and for subtype basal-like or not basal-like</measure>
    <time_frame>12 months</time_frame>
    <description>expression of LAG3; organization of immune system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of predictive factors of TILs quantification for response to neoadjuvant chemotherapy and disease free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation between TILs and TILs substypes quantification (on microbiopsy) and the histological response after neoadjuvant chemotherapy (pCR versus non pCR): determination of predictive factors for response to chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of predictive factors of PDL1 expression for response to neoadjuvant chemotherapy and disease free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation between PDL1 expression on microbiopsy and the histological response after neoadjuvant chemotherapy (pCR versus non pCR): determination of predictive factors for response to chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of predictive factors of TIM3 for response to neoadjuvant chemotherapy and disease free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation between TIM3 expression on microbiopsy and the histological response after neoadjuvant chemotherapy (pCR versus non pCR): determination of predictive factors for response to chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of predictive factors of LAG3 for response to neoadjuvant chemotherapy and disease free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation between LAG3 expression on microbiopsy and the histological response after neoadjuvant chemotherapy (pCR versus non pCR): determination of predictive factors for response to chemotherapy.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biomarker evolution</intervention_name>
    <description>analysis of a list of biomarkers on triple negative breast tumors samples before and after neoadjuvant therapy</description>
    <other_name>triple negative breast cancer biomarker evolution</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      microbiopsy of the breast primary tumor preserved in FFPE and of the operative part preserved
      in FFPE.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        100 samples
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Samples from triple negative BC patients, patients treated by neoadjuvant chemotherapy
             ( FEC or EC than taxanes) Patients consent to use their samples.

        Exclusion Criteria:

          -  Samples not available before or after neoadjuvant chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Pusztai L, Foldi J, Dhawan A, DiGiovanna MP, Mamounas EP. Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. Lancet Oncol. 2019 Jul;20(7):e390-e396. doi: 10.1016/S1470-2045(19)30158-5. Review.</citation>
    <PMID>31267973</PMID>
  </results_reference>
  <results_reference>
    <citation>Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 1;25(28):4414-22. Epub 2007 Sep 4.</citation>
    <PMID>17785706</PMID>
  </results_reference>
  <results_reference>
    <citation>Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Review. Erratum in: Lancet. 2019 Mar 9;393(10175):986.</citation>
    <PMID>24529560</PMID>
  </results_reference>
  <results_reference>
    <citation>von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.</citation>
    <PMID>30516102</PMID>
  </results_reference>
  <results_reference>
    <citation>Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.</citation>
    <PMID>28564564</PMID>
  </results_reference>
  <results_reference>
    <citation>Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014 Sep 20;32(27):2959-66.</citation>
    <PMID>25071121</PMID>
  </results_reference>
  <results_reference>
    <citation>Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013 Mar 1;31(7):860-7. doi: 10.1200/JCO.2011.41.0902. Epub 2013 Jan 22.</citation>
    <PMID>23341518</PMID>
  </results_reference>
  <results_reference>
    <citation>Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.</citation>
    <PMID>30650045</PMID>
  </results_reference>
  <results_reference>
    <citation>DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009 Aug 4;16(2):91-102. doi: 10.1016/j.ccr.2009.06.018.</citation>
    <PMID>19647220</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011 May 20;29(15):1949-55. doi: 10.1200/JCO.2010.30.5037. Epub 2011 Apr 11.</citation>
    <PMID>21483002</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012 Apr;132(2):545-53. doi: 10.1007/s10549-011-1620-1. Epub 2011 Jun 14.</citation>
    <PMID>21671016</PMID>
  </results_reference>
  <results_reference>
    <citation>Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013 Jul;123(7):2873-92. doi: 10.1172/JCI67428. Epub 2013 Jun 17.</citation>
    <PMID>23778140</PMID>
  </results_reference>
  <results_reference>
    <citation>Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011 Sep;121(9):3609-22. doi: 10.1172/JCI45816. Epub 2011 Aug 15.</citation>
    <PMID>21841316</PMID>
  </results_reference>
  <results_reference>
    <citation>Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006 Dec 1;24(34):5373-80.</citation>
    <PMID>17135638</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, Green AR. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat. 2011 May;127(1):99-108. doi: 10.1007/s10549-010-0987-8. Epub 2010 Jun 17.</citation>
    <PMID>20556505</PMID>
  </results_reference>
  <results_reference>
    <citation>Thibaudin M, Chaix M, Boidot R, Végran F, Derangère V, Limagne E, Berger H, Ladoire S, Apetoh L, Ghiringhelli F. Human ectonucleotidase-expressing CD25(high) Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. Oncoimmunology. 2015 Jul 6;5(1):e1055444. eCollection 2016.</citation>
    <PMID>26942062</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2012 Feb;65(2):159-63. doi: 10.1136/jclinpath-2011-200355. Epub 2011 Nov 2.</citation>
    <PMID>22049225</PMID>
  </results_reference>
  <results_reference>
    <citation>Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014 Mar;25(3):611-8. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Erratum in: Ann Oncol. 2015 Jul;26(7):1518.</citation>
    <PMID>24401929</PMID>
  </results_reference>
  <results_reference>
    <citation>Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, Watanabe G, Tada H, Suzuki A, Ohuchi N, Ishida T. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015 Sep 4;17:124. doi: 10.1186/s13058-015-0632-x.</citation>
    <PMID>26341640</PMID>
  </results_reference>
  <results_reference>
    <citation>Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1437.</citation>
    <PMID>26515496</PMID>
  </results_reference>
  <results_reference>
    <citation>Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Jan 1;28(1):105-13. doi: 10.1200/JCO.2009.23.7370. Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708.</citation>
    <PMID>19917869</PMID>
  </results_reference>
  <results_reference>
    <citation>Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015 Mar 20;33(9):983-91. doi: 10.1200/JCO.2014.58.1967. Epub 2014 Dec 22.</citation>
    <PMID>25534375</PMID>
  </results_reference>
  <results_reference>
    <citation>Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011 Jul;224(3):389-400. doi: 10.1002/path.2866. Epub 2011 Mar 25.</citation>
    <PMID>21437909</PMID>
  </results_reference>
  <results_reference>
    <citation>Burugu S, Gao D, Leung S, Chia SK, Nielsen TO. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol. 2017 Dec 1;28(12):2977-2984. doi: 10.1093/annonc/mdx557.</citation>
    <PMID>29045526</PMID>
  </results_reference>
  <results_reference>
    <citation>Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.</citation>
    <PMID>25214542</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post neo adjuvant therapy</keyword>
  <keyword>immune micro environment</keyword>
  <keyword>biomerker chacterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

